Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Media

The FT, Sky News, Bloomberg, WSJ, along with over 77 other leading press organisations worldwide quote our data and insight and consider us a trusted, independent source.

Upcycled foods offer manufacturers opportunity to cut waste and protect margins while appealing to eco-minded consumers, says GlobalData

Upcycled foods refer to products made by repurposing surplus ingredients and food production by-products that would otherwise go to waste, turning them into new, value-added items. As manufacturers face ongoing cost pressures and increasing scrutiny of waste across the supply chain, upcycling is emerging as a practical route to reduce waste, improve resource efficiency, and […]
Read more

Long-term data continue to bolster Trikafta’s dominant position in the cystic fibrosis market, says GlobalData

Positive long-term data for Trikafta, that was presented at the ATS 2026 International Conference, reinforces the therapy’s efficacy in adult cystic fibrosis (CF) patients with at least one F508del allele. The findings highlighted improvements in clinical and biochemical parameters, strengthening Trikafta’s leadership in the CF market and supporting informed patient monitoring and broader post-authorization market […]
Read more

China mobile services growth to be led by 5G and data demand through 2030, forecasts GlobalData

China’s mobile services market is set for a steady but modest revenue growth through 2030, as rising mobile data service revenues offset continued decline in voice and messaging revenues, says GlobalData, a leading intelligence and productivity platform. GlobalData’s China Mobile Communications Forecast (Q4 2025) reveals that the country’s mobile services revenue is expected to grow at […]
Read more

FDA accelerated approval of Hepcludex to address serious unmet need in US HDV market, says GlobalData

The US Food and Drug Administration (FDA) has recently granted accelerated approval to Gilead Sciences’ antiviral, Hepcludex (bulevirtide-gmod), for the treatment of adults with chronic hepatitis delta virus (HDV) infection without cirrhosis or with compensated cirrhosis. Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone […]
Read more

Insurance AI adoption tempered by systemic risks and structural vulnerabilities, reveals GlobalData

Artificial Intelligence (AI) adoption accelerates across the insurance ecosystem, yet underlying market realities temper widespread optimism. While intense competitive pressure forces insurers, brokers and reinsurers to fast-track AI-enabled tools, critical systemic risk concerns persist. Industry stakeholders increasingly flag structural vulnerabilities, warning that current models lack the requisite maturity for enterprise-wide deployment, reveals GlobalData, a leading […]
Read more

SpaceX’s IPO draws influencers’ attention as integrated aerospace and AI powerhouse, reveals GlobalData

SpaceX became a primary focus for influencers on X during mid-May 2026 after the company filed for an initial public offering (IPO). The filing reveals a targeted valuation of approximately $2 trillion and highlights a strategy to combine orbital transportation with massive AI computing infrastructure. This strategic shift caught the attention of influencers as it […]
Read more

UK VC funding value crosses $10 billion during January-April 2026, reveals GlobalData

Venture capital (VC) funding activity in the UK accelerated sharply during January-April 2026, with total investment value doubling to $10.5 billion even as the number of deals edged down slightly by around 2% year-on-year (YoY), reveals the Financial Deals Database of GlobalData, a leading intelligence and productivity platform. Aurojyoti Bose, Lead Analyst at GlobalData, comments: […]
Read more

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036, forecasts GlobalData

Europe’s Treponema pallidum tests market is expected to witness steady growth, driven by the increasing burden of syphilis, growing concerns around delayed diagnosis, and expanding focus on sexually transmitted infections (STIs) surveillance and early disease detection. The resurgence of syphilis across multiple European countries is reinforcing the need for timely diagnostic interventions, supporting wider adoption […]
Read more

BT Mobile’s return signals nostalgia-led brand pivot despite EE convergence gains, says GlobalData

Three years after BT UK repositioned its secondary brand EE as the flagship brand for its residential fixed-mobile convergence push, the company has decided to reinstate ‘BT Mobile’ for ‘BT Broadband’ customers. Still, EE has largely delivered on its original convergence objectives, according to GlobalData, a leading intelligence and productivity platform. Natasha Rybak, Principal Analyst […]
Read more

Magnesium glycinate gains traction as consumer appetite for wellness benefits grows, says GlobalData

UK drinks company Trip has recently launched two products—Dream Powder and Dream Gummies—formulated with magnesium glycinate. These innovative products—launched in March and April of this year—claim to support “calm nights”. The launches highlight the growing consumer appetite for supplements with wellness benefits, as consumers look to improve various health outcomes. This is substantiated by a 2025 […]
Read more

US strengthens global VC landscape dominance with 178% YoY jump in funding value during January-April 2026, reveals GlobalData

The US strengthened its dominance in global venture capital (VC) landscape during January-April 2026, riding on a stable deal-making momentum alongside a sharp surge in invested capital. While the total number of VC deals announced in the US edged up 1% year-on-year (YoY), the corresponding total VC funding value jumped by a massive 178%, according […]
Read more

ATS 2026: TETON-PPF study reinforces inhaled therapies potential in progressive pulmonary fibrosis, says GlobalData

Emerging Phase III evidence for inhaled treprostinil in progressive pulmonary fibrosis (PPF) is reinforcing industry expectations that combination therapy will shape the next phase of fibrotic lung disease treatment. TETON-PPF trial data presented at the 2026 American Thoracic Society (ATS) International Conference highlights the potential for inhaled therapies to complement existing antifibrotics, while intensifying competitive […]
Read more

ATS 2026: Jascayd reinforces combination therapy shift in US pulmonary fibrosis treatment, says GlobalData

New US subgroup data for Jascayd in idiopathic and progressive pulmonary fibrosis (IPF/PPF) is reinforcing the industry shift toward combination antifibrotic therapy in fibrotic lung disease management. Findings suggest the therapy can deliver meaningful clinical benefit alongside existing standard-of-care treatments, strengthening its commercial positioning as competitive intensity accelerates across the evolving pulmonary fibrosis treatment landscape, […]
Read more
1 … 4 5 6 7 8 … 770